said its subsidiary hVivo has signed a deal with a major pharmaceutical client to manufacture a virus for use in human challenge studies.
Manufacturing has already begun, and the work is expected to be completed by the end of the third quarter.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:
Congrats Cathal.